æ¨ä»ã³ããã¯ã¯ãã³æ¥ç¨®å¾ã®è¢«å®³ãåãä¸ããããããã«ãªã£ã¦ãã¦ããããå®éã®è¢«å®³ã®å¤§ããã«ã¤ãã¦ã¯è©ä¾¡ãä¸ååãªç¶æ³ã§ãããä»åãé¦ç¸å®é¸ã®ãã¼ã ãã¼ã¸ãæ°åã³ããã¯ã¯ãã³ã«ã¤ãã¦ãã¨ãã¸ã¿ã«åºã®ã¯ã¯ãã³æ¥ç¨®è¨é²ï¼VRSï¼ãçºè¡¨ãã¦ãããã¼ã¿ããã¨ã«ã³ããã¯ã¯ãã³3åæ¥ç¨®å¾ã®å»çå¾äºè
ã®æ»äº¡çãæ±ããçµ±è¨å¦çã«æ¤è¨ããã®ã§å¯ç¨¿ããã å½ã¯COVID-19 ã³ããã¯ã¯ãã³3åç®ã®æ¥ç¨®ãå»çå¾äºè
ã«ä»¤å3å¹´ã®12æã«åªå
æ¥ç¨®ãè¡ãæ¹éã¨ãããNHKã®å ±éã§ã¯ç´104ä¸äººã®å»çå¾äºè
ãå
è¡æ¥ç¨®ãè¡ãã¨ãªã£ã¦ãããé¦ç¸å®é¸ã®çºè¡¨ã§ã¯1,037,377人ãããã¸ã¿ã«åºã®VRSãªã¼ãã³ãã¼ã¿ã§ã¯1,037,330人ã3åç®ã®æ¥ç¨®ã令å3å¹´12æä¸ã«è¡ã£ã¦ããä¸è´ããã 次ã«é¦ç¸å®é¸ã®ãã¼ã ãã¼ã¸ã®ãæ°åã³ããã¯ã¯ãã³ã«ã¤ãã¦ãã«ããã¦ããé½éåºçå¥çã®å®ç¸¾ãã¨ããexcelã®è¡¨ãé²è¦§ã§ããã ãã®ãã¼
{{#tags}}- {{label}}
{{/tags}}